Phase I study of bisantrene in acute nonlymphoblastic leukemia. 1985

M Marty, and C Ferme, and C Gisselbrecht, and H Guy, and M J Clark, and A Bancillon, and M Boiron

A phase I study of bisantrene using a daily injection for 5 days was undertaken in adult patients with relapsing acute nonlymphoblastic leukemia. Seventeen patients received 27 courses, with daily doses ranging from 75 to 250 mg/m2. Although gastrointestinal toxicity and alopecia were rare, hematological toxicity occurred in 85% of the patients. There was cholestasis unrelated to infectious events in 27% of the courses, as well as reversible renal failure in eight of 27 evaluable courses. Responses (complete + partial) were obtained in 35% +/- 10% of the patients. The recommended dose for phase II study is 200 mg/m2/day X 7.

UI MeSH Term Description Entries
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008297 Male Males
D002779 Cholestasis Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS). Bile Duct Obstruction,Biliary Stasis,Bile Duct Obstructions,Biliary Stases,Cholestases,Duct Obstruction, Bile,Duct Obstructions, Bile,Obstruction, Bile Duct,Obstructions, Bile Duct,Stases, Biliary,Stasis, Biliary
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000873 Anthracenes A group of compounds with three aromatic rings joined in linear arrangement.
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D013921 Thrombocytopenia A subnormal level of BLOOD PLATELETS. Thrombopenia,Thrombocytopenias,Thrombopenias

Related Publications

M Marty, and C Ferme, and C Gisselbrecht, and H Guy, and M J Clark, and A Bancillon, and M Boiron
December 1989, American journal of clinical oncology,
M Marty, and C Ferme, and C Gisselbrecht, and H Guy, and M J Clark, and A Bancillon, and M Boiron
February 2021, European journal of haematology,
M Marty, and C Ferme, and C Gisselbrecht, and H Guy, and M J Clark, and A Bancillon, and M Boiron
July 1979, Cancer,
M Marty, and C Ferme, and C Gisselbrecht, and H Guy, and M J Clark, and A Bancillon, and M Boiron
January 2000, Terapevticheskii arkhiv,
M Marty, and C Ferme, and C Gisselbrecht, and H Guy, and M J Clark, and A Bancillon, and M Boiron
September 1989, Gematologiia i transfuziologiia,
M Marty, and C Ferme, and C Gisselbrecht, and H Guy, and M J Clark, and A Bancillon, and M Boiron
February 1980, The New England journal of medicine,
M Marty, and C Ferme, and C Gisselbrecht, and H Guy, and M J Clark, and A Bancillon, and M Boiron
February 1980, The New England journal of medicine,
M Marty, and C Ferme, and C Gisselbrecht, and H Guy, and M J Clark, and A Bancillon, and M Boiron
January 1989, Acta haematologica,
M Marty, and C Ferme, and C Gisselbrecht, and H Guy, and M J Clark, and A Bancillon, and M Boiron
January 1982, Cancer chemotherapy and pharmacology,
M Marty, and C Ferme, and C Gisselbrecht, and H Guy, and M J Clark, and A Bancillon, and M Boiron
January 1990, Haematology and blood transfusion,
Copied contents to your clipboard!